CiteScore: 1.5     h-index: 24

Document Type : Original Article


1 Department of Pharmaceutical Chemistry, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan

2 Department of Pharmacy, Quaid-e-Azam University, Islamabad

3 Interdisciplinary Research Centre in Biomedical Materials (IRCBM) COMSATS, Institute of Information Technology, Lahore

4 Department of Pathology, Bacha Khan Medical College, Mardan

5 Department of Tissue Engineering and Applied Cell Sciences, Tehran University of Medical Sciences, Iran


Recently, infectious diseases have increased enormously, causing a major threat to public health despite the marvelous progress in the medicinal chemistry. Fused pyrazole derivatives are having a wide range of pharmacological activities, playing a vital role as potential therapeutic agents in various pathological conditions. In the present study, novel fused pyrazoles derivatives were synthesized and evaluated for protein kinase inhibition, antioxidant, and antimicrobial activities. 3-Methyl-5-pyrazolone was first prepared by treating ethyl acetoacetate with hydrazine hydrate in absolute ethanol. Then it was treated with different aromatic aldehydes (benzaldehyde, salicylaldehyde, vanillin, 4-diamethylaminobanzaldehyde, and cinnamaldehyde) to form benzylidene derivatives of pyrazoles. These substituted pyrazoles were then treated with hydrazine and phenylhydrazine to produce fused pyrazole ring systems. The synthesized compounds were purified by recrystallization, and then characterized using the spectroscopic techniques. All the compounds exhibited moderate antibacterial activity. Antioxidant potential was determined by three methods and most of the compounds exhibited good antioxidant potential. Two compounds including, 5a and 5e demonstrated protein kinase inhibitory activity. The results indicated that, the fused pyrazoles ring systems possess prominent biological properties.

Graphical Abstract

Synthesis, Characterization and Biological Evaluation of Novel 3-Methyl-5-pyrazolone Derivatives


Main Subjects

[1].   Schiel M.A., Chopa A.B., Silbestri G.F., Alvarez M.B., Lista A.G., Domini C.E.,  Use of ultrasound in the synthesis of heterocycles of medicinal interest, in Green synthetic approaches for biologically relevant heterocycles. Elsevier. 2015
[2].  Newman D.J., Cragg G.M.,J. Nat. Prod., 2007, 70:461
[3].  Nelson K.M., Dahlin J.L., Bisson J., Graham J., Pauli G.F., Walters M.A., J. Med. Chem., 2017, 60:1620
[4].  Vuorela P., Leinonen M., Saikku P., Tammela P., Rauha J.P., Wennberg T., Vuorela H., Natural products in the process of finding new drug candidates. Cur. Med. Chem., 2004, 11: 1375
[5].  Gordon E.M., Barrett R.W., Dower W.J., Fodor, S.P., Gallop M.A.,  J. Med. Chem.,  1994, 37: 1385
[6].  Nepali K., Sharma S., Sharma M., Bedi P.M.S., Dhar K.L., Eur. J. Med. Chem., 2014, 77: 422
[7].  Baumann M., Baxendale I.R., Ley S.V., Mol. Divers.,  2011, 15:613
[8].  Yusuf, M., Jain P., Arab. J. Chem., 2014, 7:553
[9].  Das D., Banerjee R., Mitra A., J. Chem. Pharm. Res., 2014, 6:108
[10].   A Bekhit, A., Hymete, A., Bekhit, E.D.A., Damtew, A. and Y Aboul-Enein, H., Mini Rev. Med. Chem., 2010, 10:1014
[11].   Yerragunta V., Suman D., Swamy K., Anusha V., Patil, P, Naresh M., PharmaTutor, 2014, 2:40
[12].        Schmidt A., Dreger A., Cur.t Org. Chem., 2011, 15: 1423
[13].   Bhat B.A., Dhar K.L., Puri S.C., Saxena A.K., Shanmugavel M., Qazi G.N., Bioorg. Med. Chem. Lett., 2005, 15:3177
[14].   Habeeb A.G., Praveen Rao P., Knaus E.E., J. Med. Chem., 2001, 44:3039
[15].   Karrouchi K., Radi S., Ramli Y., Taoufik J., Mabkhot Y.N., Al-Aizari F.A., Molecules, 2018, 23:134
[16].   Rashad A.E., Hegab M.I., Abdel-Megeid R.E., Fathalla N., Abdel-Megeid F.M., Eur. J. Med. Chem., 2009, 44:3285
[17].   Alberti M.J., Baldwin I.R., Cheung M., Cockerill S., Flack S., Harris P.A., Jung D.K., Peckham G., Peel M.R., Badiang J.G., Stevens K., Fused pyrazole derivatives being protein kinase inhibitors. 2007. U.S. Patent 7,166,597
[18].   Potts K., Chem. Rev., 1961, 61:87
[19].   Nallasivan P.K., Pharm M., Synthesis and biological evaluation of pyrazole derivatives and some other heterocyclic compounds. Thesis. 2016
[20].   Li M., Zhao B.X., Eur. J. Med. Chem., 2014, 85:311
[21].   Kumar K.A., Jayaroopa P., Int. J. Pharmtech Res., 2013, 5:1473
[22].   Cottineau B., Toto P., Marot C., Pipaud A., Chenault J., Bioorg. Med. Chem. Lett., 2002, 12:2105
[23].   Holla B.S., Mahalinga M., Karthikeyan M.S., Akberali P.M., Shetty N.S., Bioorg. Med. Chem. Lett., 2006, 14:2040
[24].   Schenone S., Bruno O., Ranise A., Brullo C., Bondavalli F., Filippelli W., Mazzeo F., Capuano A., Falcone G., II Farmaco, 2003, 58:845
[25].   Kuo S.C., Huang L.J., Nakamura H., J. Med. Chem., 1984, 27:539
[26].   Wong P.C., Pinto D.J., Knabb R.M., Cardiovasc. Drug Rev., 2002, 20:137
[27].   Lin R., Chiu G., Yu Y., Connolly P.J., Li S., Lu Y., Adams M., Fuentes-Pesquera A.R., Emanuel S.L., Greenberger L.M., Bioorg. Med. Chem. Lett., 2007, 17:4557
[28].   Mohamed M.F., Mohamed M.S., Shouman S.A., Fathi M.M., Abdelhamid I.A., Appl. Biochem. Biotechnol., 2012, 168:1153
[29].   Kumari S., Paliwal S., Chauhan R., Synth. Commun., 2014, 44:1521
[30].   DeWald H.A., Lobbestael S., Butler D.E., J. Med. Chem.,  1977, 20:1562
[31].   Palaska E., Aytemir M., Uzbay I.T., Erol D., Eur. J. Med. Chem.,  2001, 36:539
[32].   Abdel-Aziz M., Abuo-Rahma G.E.-D.A., Hassan A.A., Eur. J. Med. Chem., 2009, 44:3480
[33].   Bandgar B.P., Gawande S.S., Bodade R.G., Gawande N.M., Khobragade C.N., Bioorg. Med. Chem. Lett., 2009, 17:8168
[34].   Sherman T.D., Duke M.V., Clark R.D., Sanders E.F., Matsumoto H., Duke S.O., Pesticide Biochemistry and Physiology, 1991, 40:236
[35].   Wu J., Song B.A., Hu D.Y., Yue M., Yang S., Pest Manag. Sci., 2012, 68:801
[36].   Dizdaroglu Y., Albay C., Arslan T., Ece A., Turkoglu E.A., Efe A., Senturk M., Supuran C.T., Ekinci D., J. Enzyme Inhib. Med., 2020, 35:289
[37].   Straub A., Feurer A., Alonso-Alija C., Stasch J.P., Perzborn E., Hütter J., Dembowsky K., Stahl E., Bayer A.G., Substituted pyrazole derivatives condensed with six-membered heterocyclic rings. U.S. Patent 6,743,798. 2004. 
[38].   Mariappan G., Saha B.P., Sutharson L., Haldar A. Indian J. Chem., 2010, 498:1671
[39].   Bondock S., Fadaly W., Metwally M.A., Eur. J. Med. Chem., 2010, 45:3692
[40].   Qian Z.J., Jung W.K., Kim S.K., Bioresour. Technol., 2008, 99:1690
[41].   Saleem S., Jafri L., ul Haq I., Chang L.C., Calderwood D., Green B.D., Mirza B., J. Ethnopharmacol., 2014, 156:26
[42].   Wang H.C., Hu Z.Q., Wang Y., Chen H.B., Huang X.M., Sci. Hortic., 2011, 129:784
[43].   Joshi A., Sain D.K., Thadhaney B., Ojha S., Hussain N., Talesara G.L., Indian J. Chem.,2010, 49:965
[44].   Molyneux P., J. Sci. Technol., 2004, 26:211
[45].   Prieto P., Pineda M., Aguilar M., Anal. Biochem., 1999, 269:337
[46].   Benzie I.F., Strain J., [2] Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration, in Methods in enzymology. Elsevier. Academic press. 1999